Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent therapy in advanced melanoma (MEL)

被引：0
|
作者：
Sznol, Mario
Kluger, Harriet M.
Callahan, Margaret K.
Postow, Michael Andrew
Gordon, Ruth Ann
Segal, Neil Howard
Rizvi, Nalyer A.
Lesokhin, Alexander M.
Atkins, Michael B.
Kirkwood, John M.
Burke, Matthew M.
Ralabate, Amanda L.
Rivera, Angel L.
Kronenberg, Stephanie Anne
Agunwamba, Blessing
Feely, William
Hong, Quan
Krishnan, Suba
Gupta, Ashok Kumar
Wolchok, Jedd D.
机构：
[1] Yale Canc Ctr, New Haven, CT USA
[2] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
[3] Georgetown Lombardi Comprehens Canc Ctr, Washington, DC USA
[4] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA
[5] Bristol Myers Squibb Co, Princeton, NJ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LBA9003
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Nivolumab (anti-PD-1; BMS-936558; ONO-4538) in patients with advanced solid tumors: Survival and long-term safety in a phase I trial.
    Topalian, Suzanne Louise
    Sznol, Mario
    Brahmer, Julie R.
    McDermott, David F.
    Smith, David C.
    Gettinger, Scott N.
    Taube, Janis M.
    Drake, Charles G.
    Pardoll, Drew M.
    Powderly, John D.
    Carvajal, Richard D.
    Sosman, Jeffrey Alan
    Atkins, Michael B.
    Antonia, Scott J.
    Spigel, David R.
    Lawrence, Donald P.
    Kollia, Georgia
    Gupta, Ashok Kumar
    Wigginton, Jon M.
    Hodi, F. Stephen
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [22] Safety and antitumor activity of biweekly MDX-1106 (Anti-PD-1, BMS-936558/ONO-4538) in patients with advanced refractory malignancies
    Sznol, M.
    Powderly, J. D.
    Smith, D. C.
    Brahmer, J. R.
    Drake, C. G.
    McDermott, D. F.
    Lawrence, D. P.
    Wolchok, J. D.
    Topalian, S. L.
    Lowy, I.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [23] Safety and response with nivolumab (anti-PD-1; BMS-936558, ONO-4538) plus erlotinib in patients (pts) with epidermal growth factor receptor mutant (EGFR MT) advanced NSCLC.
    Rizvi, Naiyer A.
    Chow, Laura Quan Man
    Borghaei, Hossein
    Shen, Yun
    Harbison, Christopher
    Alaparthy, Suresh
    Chen, Allen C.
    Gettinger, Scott N.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [24] Safety and Efficacy of First-Line Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) and Ipilimumab in Non-Small Cell Lung Cancer (NSCLC)
    Antonia, S. J.
    Gettinger, S.
    Goldman, J.
    Chow, L. Q.
    Juergens, R.
    Borghaei, H.
    Brahmer, J. R.
    Shen, Y.
    Harbison, C.
    Chen, A. C.
    Ready, N. E.
    Rizvi, N. A.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 90 : S32 - S33
  • [25] Efficacy and safety of anti-PD-1 antibody (Nivolumab: BMS-936558, ONO-4538) in patients with platinum-resistant ovarian cancer.
    Hamanishi, Junzo
    Mandai, Masaki
    Ikeda, Takafumi
    Minami, Manabu
    Kawaguchi, Atsushi
    Matsumura, Noriomi
    Abiko, Kaoru
    Baba, Tsukasa
    Yamaguchi, Ken
    Ueda, Akihiko
    Kanai, Masashi
    Mori, Yukiko
    Matsumoto, Shigemi
    Murayama, Toshinori
    Chikuma, Shunsuke
    Morita, Satoshi
    Yokode, Masayuki
    Shimizu, Akira
    Honjo, Tasuku
    Konishi, Ikuo
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [26] Phase I/II, open-label study of nivolumab (anti-PD-1; BMS-936558, ONO-4538) as monotherapy or combined with ipilimumab in advanced or metastatic solid tumors.
    Callahan, Margaret K.
    Bendell, Johanna C.
    Chan, Emily
    Morse, Michael
    Pillai, Rathi Narayana
    Bono, Petri
    Jaeger, Dirk
    Evans, T. R. Jeffry
    Chau, Ian
    Calvo, Emillano
    Le, Dung T.
    Ott, Patrick Alexander
    Taylor, Matthew Hiram
    Sharma, Padmanoo
    Antonia, Scott Joseph
    Sharkey, Brian
    Christensen, Olaf
    Amin, Asim
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [27] Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with sunitinib or pazopanib in patients (pts) with metastatic renal cell carcinoma (mRCC).
    Amin, Asim
    Plimack, Elizabeth R.
    Infante, Jeffrey R.
    Ernstoff, Marc S.
    Rini, Brian I.
    McDermott, David F.
    Knox, Jennifer J.
    Pal, Sumanta Kumar
    Voss, Martin Henner
    Sharma, Padmanee
    Kollmannsberger, Christian K.
    Heng, Daniel Yick Chin
    Spratlin, Jennifer L.
    Shen, Yun
    Kurland, John F.
    Gagnier, Paul
    Hammers, Hans J.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [28] First-line nivolumab (anti-PD-1; BMS-936558, ONO-4538) monotherapy in advanced NSCLC: Safety, efficacy, and correlation of outcomes with PD-L1 status.
    Gettinger, Scott N.
    Shepherd, Frances A.
    Antonia, Scott Joseph
    Brahmer, Julie R.
    Chow, Laura Quan Man
    Juergens, Rosalyn A.
    Borghaei, Hossein
    Shen, Yun
    Harbison, Christopher
    Alaparthy, Suresh
    Chen, Allen C.
    Rizvi, Naiyer A.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [29] Nivolumab (anti-PD-1, BMS-936558, ONO-4538) in patients (pts) with advanced non-small-cell lung cancer (NSCLC): Survival and clinical activity by subgroup analysis.
    Brahmer, Julie R.
    Horn, Leora
    Gandhi, Leena
    Spigel, David R.
    Antonia, Scott Joseph
    Rizvi, Naiyer A.
    Powderly, John D.
    Heist, Rebecca Suk
    Carvajal, Richard D.
    Jackman, David Michael
    Sequist, Lecia V.
    Smith, David C.
    Leming, Philip D.
    Topalian, Suzanne Louise
    Hodi, F. Stephen
    Sznol, Mario
    Harbison, Christopher
    Kollia, Georgia
    Gupta, Ashok Kumar
    Gettinger, Scott N.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [30] Randomized phase IIb study of nivolumab (anti-PD-1; BMS-936558, ONO-4538) alone or in combination with ipilimumab versus bevacizumab in patients (pts) with recurrent glioblastoma (GBM).
    Sampson, John Howard
    Viahovic, Gordana
    Desjardins, Annick
    Friedman, Henry S.
    Baehring, Joachim M.
    Hafler, David
    Rollin, Linda
    Coric, Viad
    Perez, Susan N.
    Reardon, David A.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
12345